It really is pathetic that RVX is rarely a part of the conversation in most media releases such as the one Barsax just posted. The write ups in Cell etc are top notch scientific recognition but it is up to management to do the requisite follow up. To me every opportunity should be taken to get the Resverlogix name and science out front and center which along with a few prudent business steps might garner wider interest in the company and actually drive the share price higher to where some reasonable financings can take place. Reasonable for a company with a BTD on a potential blockbuster drug and a further potential CoVid opportunity. IMO from the outside it sure seems management is apparently disinterested in doing anything resembling a good job.